TruScreen detection of cervical tissues for high-risk human papillomavirus-infected women during the COVID-19 pandemic.
Future Oncol
; 17(10): 1197-1207, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1112570
ABSTRACT
Aims:
To evaluate the efficacy of TruScreen (TS01) for high-risk human papillomavirus (HR-HPV) women compared with other methods in reducing colposcopy referral rates in hospitals.Methods:
A single-center, prospective, case-control study was conducted from December 2019 to June 2020.Results:
Among 139 (46.2%) HR-HPV-positive patients, 58 were CIN1, 52 were CIN2-3 and 29 had cervical cancer (n = 29). The sensitivity and specificity of detecting CIN2+ by TS01, colposcopy and HPV16/18 testing were 96.3% and 46.4%, 85.2% and 40.5% and 59.3% and 74.1%, respectively. The highest sensitivity was 96.3% at HPV16/18 and TS01 (each positive results), and the highest specificity was 83.6% at HPV16/18 and TS01 (both positive) for CIN2+ compared with the other methods.Conclusion:
TS01 is a noninvasive screening method and can be used to diagnose cervical lesions quickly. It is especially suitable as triage tool for HR-HPV-positive women facing SARS-CoV-2 exposure and infection risks in hospital.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Uterine Cervical Dysplasia
/
Uterine Cervical Neoplasms
/
Papillomavirus Infections
/
Early Detection of Cancer
/
SARS-CoV-2
/
COVID-19
Type of study:
Cohort study
/
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
/
Young adult
Language:
English
Journal:
Future Oncol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS